Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Faron Pharmaceuticals Oy
  6. News
  7. Summary
    FARN   FI4000153309

FARON PHARMACEUTICALS OY

(FARN)
  Report
Delayed Quote. Delayed London Stock Exchange - 11/26 11:35:24 am
310 GBX   -1.59%
11/09Faron awarded EUR 3.8 Million in Arbitration Case
AQ
10/07FARON PHARMACEUTICALS OY : Exercise of options
AQ
10/05TR-1 : Standard form for notification of major holdings
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Faron Pharmaceuticals Oy : Registration of Placing Shares with Trade Register

10/01/2021 | 09:01am EST

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS ONLY DIRECTED AT PERSONS IN THE UNITED KINGDOM THAT ARE QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 2(E) OF REGULATION 2017/1129/EU AS INCORPORATED INTO UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 THAT ARE ALSO (I) INVESTMENT PROFESSIONALS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER") AND/OR (II) HIGH NET WORTH ENTITIES, AND OTHER PERSONS TO WHOM IT MAY LAWFULLY BE COMMUNICATED, FALLING WITHIN ARTICLE 49(2)(A) TO (E) OF THE ORDER (EACH SUCH PERSON BEING REFERRED TO AS A "RELEVANT PERSON"). ACCORDINGLY, THIS ANNOUNCEMENT AND ITS CONTENTS MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. PERSONS INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED TO INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS.

 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Registration of Placing Shares with the Trade Register

 

Capitalised terms used in this announcement have the meanings given to them in the announcement made at 4.30 p.m. GMT / 6.30 p.m. EEST on 30 September 2021 regarding the proposed issue and placing of new ordinary shares in the Company (the "Launch Announcement") and the subsequent announcement released at 7.00 a.m. GMT / 9.00 a.m. EEST on 1 October 2021 (the "Pricing and Results Announcement"), unless the context provides otherwise.
 

Company announcement, 1 October 2021 at 2:00 p.m. BST / 4:00 p.m.

 

EESTTURKU, FINLAND / BOSTON, MA-

Faron Pharmaceuticals Ltd (First North: FARON, AIM: FARN), the clinical stage biopharmaceutical company, has as previously announced completed the Placing. The Company announced the results of the Placing on 1 October 2021.A total of 2,763,158 Placing Shares subscribed for in the Placing have been issued and registered in the Trade Register today on 1 October 2021. The Placing Shares confer a right to dividends and other shareholder rights from their registration with the Trade Register. Following the Placing, the aggregate number of ordinary shares in the Company is 53,221,032. One ordinary share entitles to one vote in the general meeting of the Company. The Company holds no treasury shares.

 

Trading in the Placing Shares is expected to commence on First North and AIM latest on or around 5 October 2021.
 

For more information please contact:

 

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

 

Swedbank AB (publ), Finnish Branch, Financial Adviser

Mika Karikoski (Corporate Finance)

Phone: +358 (0)40 741 6959

 

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: + 44 207 213 0880

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 40 555 4727

Jukka Järvelä

Phone: +358 50 553 8990

 

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

faron@consilium-comms.com

 

Stern Investor Relations

Julie Seidel

Phone: +1 (212) 362-1200

julie.seidel@sternir.com

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous (IV) interferon beta-1a therapy for the treatment of acute respiratory distress syndrome (ARDS) and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma.  Faron is based in Turku, Finland. Further information is available at www.faron.com.

 

IMPORTANT INFORMATION
 

Market Abuse Regulation

Market soundings, as defined in Regulation (EU) No 596/2014 ("MAR"), were taken in respect of the proposed Placing with the result that certain persons became aware of inside information, as permitted by MAR. That inside information in relation to the Placing is set out in this announcement and has been disclosed as soon as possible in accordance with paragraph 7 of article 17 of MAR. Therefore, those persons that received inside information in such market sounding are no longer in possession of inside information relating to the Company and its securities.

 

MiFID II

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of: (a) retail investors, (b) investors who meet the criteria of professional clients and (c) eligible counterparties (each as defined in MiFID II); and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offer.

https://news.cision.com/faron-pharmaceuticals-oy/r/registration-of-placing-shares-with-trade-register,c3425859

https://mb.cision.com/Main/19398/3425859/1476241.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about FARON PHARMACEUTICALS OY
11/09Faron awarded EUR 3.8 Million in Arbitration Case
AQ
10/07FARON PHARMACEUTICALS OY : Exercise of options
AQ
10/05TR-1 : Standard form for notification of major holdings
AQ
10/01FARON PHARMACEUTICALS OY : Registration of Placing Shares with Trade Register
AQ
10/01FARON PHARMACEUTICALS OY : Results of Placing and Issue Price
AQ
09/30FARON PHARMACEUTICALS OY : Proposed Issue and Placing of Shares
AQ
09/17FARON PHARMACEUTICALS OY : Presentation of Updated MATINS Data at ESMO
AQ
09/17Faron Pharmaceuticals Ltd. Announces Updated Results from the Phase I/II MATINS Study
CI
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS Reports H1 Loss E..
MT
08/26FARON PHARMACEUTICALS OY : Earnings Flash (FARN.L) FARON PHARMACEUTICALS Reports H1 Revenu..
MT
More news
Financials
Sales 2021 - - -
Net income 2021 -16,8 M -19,0 M -19,0 M
Net cash 2021 10,8 M 12,2 M 12,2 M
P/E ratio 2021 -12,2x
Yield 2021 -
Capitalization 194 M 220 M 220 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 30
Free-Float 56,5%
Chart FARON PHARMACEUTICALS OY
Duration : Period :
Faron Pharmaceuticals Oy Technical Analysis Chart | FARN | FI4000153309 | MarketScreener
Technical analysis trends FARON PHARMACEUTICALS OY
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 3,65 €
Average target price 5,75 €
Spread / Average Target 57,4%
EPS Revisions
Managers and Directors
Markku Tapani Jalkanen Chief Executive Officer & Executive Director
Toni Haenninen Chief Financial Officer
Frank Murdoch Armstrong Non-Executive Chairman
Matti Karvonen Chief Medical Officer & VP-Drug Development
Jami Mandelin Research Director
Sector and Competitors
1st jan.Capi. (M$)
FARON PHARMACEUTICALS OY19.23%223
GILEAD SCIENCES, INC.20.27%87 895
BIONTECH SE273.85%73 606
REGENERON PHARMACEUTICALS34.17%67 771
WUXI APPTEC CO., LTD.24.40%62 328
VERTEX PHARMACEUTICALS-21.20%47 352